| template | feedback-response |
| --- | --- |
| purpose | Document instructor's Stage 2 + Stage 3 PR feedback and the actions taken in response |
| audience | instructor (Professor Adam W. Stauffer) |
| naming_convention | YYYY-MM-DD-{lastname}-stage2-feedback-response.md |
| courses | BUS-629 |
| stage2_original | docs/decisions/2026-05-17-cam-sectra-selection.md |
| stage2_revised | docs/decisions/2026-05-31-cam-sectra-selection-revised.md |
| stage3_artifact | models/builds/2026-05-17-cam-sectra-financials.xlsx |

# Stage 2 and Stage 3 — Instructor Feedback Response

**Author:** Hien Cam
**Date:** 2026-05-31
**Re:** Response to instructor PR feedback on Stage 2 memo (`docs/decisions/2026-05-17-cam-sectra-selection.md`) and Stage 3 workbook (`models/builds/2026-05-17-cam-sectra-financials.xlsx`)

---

## Stage 2 feedback received

**Date received:** May 22, 2026, 2:36 PM
**Score awarded:** 4.37 / 4.5 = **97.11%**

**Verbatim instructor feedback (Stage 2 rubric notes):**

> *"Prose word count is around 1153; target is 400–600. Tighten any sections that read as repetitive — a senior analyst memo is short."*

The accompanying "Looking ahead to Stage 3" note about populating the workbook with real financials from a 10-K was forward-guidance for Stage 3 work and has been addressed in `models/builds/2026-05-17-cam-sectra-financials.xlsx`.

---

## Stage 2 — My read of the feedback

The score of 97.11% indicates the substance of the memo was strong — the hypothesis design, company-selection rationale, and method section all passed without comment. The single actionable critique is **length and repetition**: the memo at submission was significantly longer than the senior-analyst-memo target.

I revisited the original memo and counted prose words at 868 (the instructor's count of ~1153 may include metadata table content, blockquote headers, and the references block; my recount excludes those). Either way, the memo exceeds the 400–600-word target by a meaningful margin and contains specific repetition patterns I had not noticed on first writing.

**Repetitive sections I identified:**

1. **Selection Rationale paragraph in Background** restated my professional context (Vietnam medical equipment, VP role at HCMC Medical Equipment Association, Digital Health agenda) in two consecutive sentences using slightly different framings.
2. **Findings H1** included an explanatory aside on "emerging-market healthcare procurement... public-hospital payment cycles 12–24 months" that, while relevant to my own market interest, did not strengthen the hypothesis — the hypothesis stands on Sectra's own SaaS-transition mechanics.
3. **Method section** contained sentence-level redundancy on currency exposure that overlaps with H3's currency framing.

---

## Stage 2 — Action taken

I have shipped a revised version of the memo at **`docs/decisions/2026-05-31-cam-sectra-selection-revised.md`** with the following changes:

| Section | Original (words) | Revised (words) | Cuts made |
|---|---:|---:|---|
| Executive Summary | 106 | 80 | Tightened the four-eligibility-criteria phrasing; removed redundant "career trajectory" close |
| Background | 287 | 120 | Compressed Selection Rationale from three multi-sentence paragraphs to three single-sentence clauses (a/b/c structure); removed the SaaS-vs-on-premise contrast paragraph (the same point is made in H1 and H2) |
| Method | 109 | 74 | Removed sentence-level repetition on currency exposure (kept the consideration list); shortened reference to data sources |
| Findings | 221 | 131 | Removed the emerging-market healthcare aside in H1; tightened CEO-guidance reference in H2; compressed parenthetical disclosures in H3 |
| Implications | 75 | 39 | Removed the "where the SaaS model's hallmark cash-flow leadership emerges" descriptive phrase — the implication speaks for itself |
| Limitations | 70 | 34 | Removed the next-steps recap (next steps are implied by the project structure) |
| **Total prose** | **868** | **478** | **45% reduction; now within 400–600 target** |

The three hypotheses (H1, H2, H3) are preserved in full because they are the analytical core of the memo. The Background's Selection Rationale is preserved in structure (the same three dimensions: industry alignment, analytical richness, international finance) but compressed in execution.

---

## Stage 2 — What I learned

The PR feedback surfaced a discipline I had not internalized: **a senior-analyst memo is a sales document for an analytical project, not a comprehensive justification of it**. The reader needs to be persuaded the company is worth analyzing, not walked through every reason it is worth analyzing. The 400–600-word target is a forcing function for that distinction.

I will apply this discipline going forward in two ways:

1. **For BUS-629 work in this project:** Stage 5's evaluated final analysis (`deliverables/2026-05-31-cam-sectra-final-analysis.md`) and spec retrospective both use a "section budget" model where each section has a target word count, set before drafting, and the writing is iterated against that budget rather than expanded to fill available space.

2. **For real-world memos in my professional work:** the same length discipline applies to internal investment-decision memos for medical-equipment distribution opportunities. The revised version of this memo is the model I will reference for those.

---

## Stage 3 feedback received

**Date received:** May 22, 2026, 2:42 PM
**Score awarded:** 8.91 / 9 = **99%**

**Verbatim instructor feedback (Stage 3 rubric notes):**

> *"Strong submission across all four criteria — balance sheet balances both years, named ranges populated, documentation complete, and ratios resolve cleanly. Stage 4 (the spec) is largely a writing task on top of what you've already built — keep the same discipline."*

**Forward guidance for Stage 4:**

> *"Stage 4 — technical specification for the LLM analysis. The spec is the input that drives Stage 5's automated ratio review. Reference named ranges directly (e.g., `BAL_assets_total_curr`, `RATIO_roe`) so the LLM can find the right cells. Use the Stage 4 HIL iteration pass to catch spec gaps before they bake into Stage 5."*

## Stage 3 — My read and action taken

Stage 3 feedback contained no actionable critique — the score of 99% with positive feedback across all four criteria (balance-sheet balance, named-range population, documentation completeness, ratio resolution) indicates the workbook was strong as submitted. **No workbook revisions are required.**

The two forward-guidance items for Stage 4 were both executed:

1. **"Reference named ranges directly."** The Stage 4 specification (`docs/specs/2026-05-30-cam-sectra-spec.md`) uses named-range notation throughout — Section 6 of the spec writes every ratio formula in `BAL_*`, `INC_*`, `RATIO_*` notation rather than cell references or English descriptions. The verification table (`analysis/validation/2026-05-31-cam-sectra-stage5-verification.md`) preserves this convention, and the final analysis references named ranges inline where structural context requires it.

2. **"Use the Stage 4 HIL iteration pass to catch spec gaps."** The HIL iteration surfaced a documented deviation between the workbook's Cover-sheet convention (`BAL_*_2024` / `BAL_*_2025`) and the implementation in the Names Manager (`BAL_*_curr` / `BAL_*_prior`). This was addressed in Stage 4 by adopting the implementation convention throughout the spec (with the Cover-sheet deviation documented in spec Section 4). The Stage 5 LLM execution validated this fix — Gemini used `_curr` / `_prior` consistently and never attempted formulas with the documented-but-not-implemented `_2024` / `_2025` literals. The Part A.4 verdict in the spec retrospective notes this as a Clear-status section directly traceable to executing the Stage 3 forward guidance.

The "keep the same discipline" instruction in the feedback was a meta-comment about maintaining the rigor demonstrated in Stage 3 (auditable named ranges, clean documentation, tight ratio resolution) when moving into the looser-format spec-writing task of Stage 4. This discipline shaped Stage 4's validation-rule section (eight V-* rules), the named-range glossary, and the patent-settlement strip-out convention — all of which Stage 5 confirmed the LLM could execute against.

---

## Stage 2 — Both files retained in repo

The original 2026-05-17 memo is preserved in `docs/decisions/2026-05-17-cam-sectra-selection.md` as a record of the submission state at Stage 2. The revised 2026-05-31 version sits alongside it and is the version the rubric's downstream work (Stages 3, 4, 5) is anchored to. Both are linked from `docs/decisions/README.md`.

---

## Cross-references

- Stage 2 original memo: `docs/decisions/2026-05-17-cam-sectra-selection.md`
- Stage 2 revised memo: `docs/decisions/2026-05-31-cam-sectra-selection-revised.md`
- Stage 3 workbook (no revisions needed): `models/builds/2026-05-17-cam-sectra-financials.xlsx`
- Stage 4 spec: `docs/specs/2026-05-30-cam-sectra-spec.md`
- Stage 5 final analysis: `deliverables/2026-05-31-cam-sectra-final-analysis.md`
- Stage 5 spec retrospective: `deliverables/2026-05-31-cam-sectra-spec-retrospective.md`
